Details for New Drug Application (NDA): 211022
✉ Email this page to a colleague
The generic ingredient in LENALIDOMIDE is lenalidomide. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the lenalidomide profile page.
Summary for 211022
Tradename: | LENALIDOMIDE |
Applicant: | Apotex |
Ingredient: | lenalidomide |
Patents: | 0 |
Suppliers and Packaging for NDA: 211022
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LENALIDOMIDE | lenalidomide | CAPSULE;ORAL | 211022 | ANDA | Apotex Corp. | 60505-4532 | 60505-4532-2 | 28 CAPSULE in 1 BOTTLE (60505-4532-2) |
LENALIDOMIDE | lenalidomide | CAPSULE;ORAL | 211022 | ANDA | Apotex Corp. | 60505-4533 | 60505-4533-2 | 28 CAPSULE in 1 BOTTLE (60505-4533-2) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 5MG | ||||
Approval Date: | Aug 30, 2022 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 10MG | ||||
Approval Date: | Aug 30, 2022 | TE: | AB | RLD: | No |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 15MG | ||||
Approval Date: | Aug 30, 2022 | TE: | AB | RLD: | No |
Complete Access Available with Subscription